Women's and Children's Hospital | Haematology and Oncology Department
Status and phase
Conditions
Treatments
About
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
Full description
Both Australia (Zero Childhood Cancer) and Canada (PROFYLE) have developed precision oncology programs for the pediatric population through which samples from childhood/adolescent cancers undergo in depth genetic profiling. OPTIMISE is a companion platform trial, which will link patients to novel targeted agents based on their tumor profile. The trial will have multiple basket arms based on the most common genetically altered pathways the investigators have identified in these childhood cancers. Each arm of the trial will be histopathology agnostic and test a rational, novel combination therapy, to maximise potential clinical benefit.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
82 participants in 2 patient groups
Loading...
Central trial contact
KOALA Manager; National Study Coordinator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal